SCHEMBL12200535

SCHEMBL12200535

CC1(C)OB(c2ccc3c(c2)c2cccc4c5cc6c7ccc(B8OC(C)(C)C(C)(C)O8)cc7c7cccc(c5cc3c24)c76)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 14/20 0.45
LPL P06858 13/20 0.45
EGFR P00533 1/20 0.40
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
CSF1R P07333 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20996065 0.90 LPL (0.51) LIPGLPLEGFRPRMT5WDR77
SCHEMBL21034968 0.90 LPL (0.51) LIPGLPLEGFRPRMT5WDR77
SCHEMBL29787170 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL15456760 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL17548647 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL2015694 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL21764502 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL311849 0.88 LPL (0.56) LIPGLPLEGFRPRMT5WDR77
SCHEMBL24628089 0.88 LIPG (0.42) LIPGLPLEGFRPRMT5WDR77
SCHEMBL32690648 0.86 PRMT5 (0.40) LIPGLPLEGFRPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765270-B2 Triazine compound and organic light emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-07-01 US disclosed
US-8765270-B2 Triazine compound and organic light emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-07-01 US disclosed
US-20110240983-A1 TRIAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2011-10-06 US disclosed
US-20110240983-A1 TRIAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2011-10-06 US disclosed
WO-2010067894-A1 TRIAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110240983-A1 TRIAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME TERT, CYP1A1, NR2E3 LIPG 4717/4885LPL 3606/4885EGFR 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.